Compare Icl Group Ltd (ICL) vs TransMedics Group Inc (TMDX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Icl Group Ltd vs TransMedics Group Inc — how do they compare? Icl Group Ltd trades at $5.3 (market cap $6.94B), while TransMedics Group Inc trades at $87.08 (market cap $3.10B). The key difference: Icl Group Ltd is far larger — about 2.2× TransMedics Group Inc's market cap, and Icl Group Ltd pays a 3.86% dividend while TransMedics Group Inc pays none. Which is the better fit depends on your goals.
| ICL | TMDX | |
|---|---|---|
Market Cap | $6.94B | $3.10B |
Sector | Basic Materials | Technology |
52-Week High | $6.84 | $150.42 |
52-Week Low | $4.80 | $61.99 |
Enterprise Value | $9.58B | $3.49B |
Dividend Yield | 3.86% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ICL trades at $5.465, up 2.34% today, with a bullish technical signal from moving averages. The company reported Q2 2026 EPS of $0.12, beating estimates, and revenue is projected to grow to $7.7B in 2026. Recent news highlights strong quarterly results and a senior notes offering. The stock shows a neutral sentiment from oscillators, while analyst consensus is entirely Hold.
The outlook is mixed; earnings beats and operational improvements support upside, but declining net margins and a unanimous Hold rating from analysts suggest limited near-term catalysts. Key risks include raw material cost pressures and foreign exchange volatility, which could impact profitability despite positive cash flow trends.
TransMedics Group (TMDX) trades at $87.02, down 1.57% today, amid mixed signals. The stock shows a bullish technical trend with moving averages supporting upside, but oscillators like RSI indicate overbought conditions near 78. Fundamentally, the company reported record Q2 2026 revenue but missed earnings estimates, with net income margin declining to 22.69% from 31.42% in 2025. Recent news highlights an ongoing investigation into fiduciary duties by Rosen Law Firm, adding uncertainty.
The outlook remains cautiously optimistic with a consensus price target of $99.57, implying 14% upside, supported by strong analyst buy ratings (69%). However, risks include earnings volatility, margin pressure from rising costs, and legal scrutiny. Investors should weigh robust revenue growth against execution risks and elevated valuation multiples like a P/E of 23.15.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Icl Group Ltd
ICL Group Ltd is a manufacturer of products based on minerals. The firm is comprised of four segments: phosphate solutions, potash, industrial products, and innovative agriculture solutions (IAS). These segments all contribute to the company's development of agriculture, food, and engineered material products and services. The company mines and manufactures potash and phosphates to be used as ingredients in fertilizers and serve as a component in the pharmaceutical and food additives industries. It is also engaged in industrial additives and materials, including flame retardants, phosphate salts, specialty phosphate blends, purified phosphoric acid, electronic-grade specialty phosphoric acids. Its geographical segments are Europe, Asia, North & South America, and the Rest of the world.
Read more on ICL →About TransMedics Group Inc
TransMedics is a pioneering medical technology company that is disrupting the organ transplant market with its Organ Care System (OCS™). By replacing traditional cold storage with portable warm perfusion, the OCS maintains donor organs in a near-physiologic state, allowing for continuous assessment and optimization. Through its National OCS Program (NOP™), TransMedics provides an end-to-end clinical and logistics solution, including a dedicated aviation fleet, to maximize the utilization of donor organs and improve patient outcomes.
Read more on TMDX →
